Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.
Yung Lyou, MD, PhD
Advertisement
Articles by Yung Lyou, MD, PhD
Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.
Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.
Advertisement
Latest Updated Articles
Dr. Lyou on Sequencing Apalutamide in Prostate CancerJuly 16th 2021
Dr. Lyou on Emerging Biomarkers in Prostate CancerJuly 19th 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
FDA Awards Orphan Drug Designation to Enzomenib for ALL
4
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
5